Adverse Drug Reactions
Adverse Drug Reactions - Related Videos
01:27
Allergic Drug Reactions
0 Views •
2023
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing numerous...
01:30
Drug Toxicity: Allergic Reactions
0 Views •
2026
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial exposure to a...
01:17
Drug Metabolism: Phase I Reactions
0 Views •
2023
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
01:14
Drug Metabolism: Phase II Reactions
0 Views •
2023
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
01:16
Drug toxicity: Idiosyncratic Reactions
0 Views •
2026
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
FAQs
Some ADRs follow the expected pharmacological action of a medicine and become more likely or severe as dose increases. Others arise unpredictably from immune responses or inherited genetic susceptibility, even when dosing follows recommendations. This distinction helps clinicians anticipate dose-related toxicity while recognizing reactions that may require a different risk assessment.
Altered metabolism can change how much drug reaches its site of action, potentially changing exposure and response. Drug interactions may produce a similar change, making treatment effects less predictable when medicines are combined. Reviewing these mechanisms helps explain why symptoms may emerge after exposure changes and why monitoring can become clinically useful.
Immune responses can produce ADRs that are not readily predicted from a medicine's usual pharmacological effects or dose. Their unpredictability contrasts with dose-related reactions, which follow a more expected relationship with exposure. Recognizing this distinction matters because clinicians cannot rely only on dose adjustment to anticipate every harmful response.
Patient factors can alter how a person responds to a medicine, while genetic susceptibility may help explain why an unpredictable reaction occurs in one individual but not another. Considering these differences supports individualized treatment rather than assuming that the same recommended regimen carries identical risk for everyone. This perspective is central to pharmacology and safer prescribing.
To assess causality, clinicians consider the symptoms, their timing in relation to treatment, the dose, relevant patient factors, and alternative explanations. This review does not depend on one observation alone; it weighs whether the pattern fits the suspected medicine better than competing causes. The result helps guide safer prescribing and individualized treatment decisions.
Laboratory tests can help identify organ injury, whereas therapeutic monitoring can reveal changing drug exposure. These tools add objective information to symptom review and timing assessment, particularly when clinicians need to determine whether a medicine is contributing to harm. Their findings support safer prescribing and more individualized treatment decisions.
Information about ADRs supports pharmacovigilance and regulatory evaluation of medicine safety. It also contributes to developing medicines with improved benefit-risk profiles by incorporating observed harms into broader treatment and safety assessments. Thus, ADR evaluation extends beyond one patient encounter, informing safer prescribing, regulatory decisions, and the future design of medicines.